Teva Pharmaceutical Industries Ltd. resumed production at an Irvine, Calif., facility that was on voluntary hold for a year following quality-control issues and regulatory intervention.

The site, which makes injectable products for the Israel-based generic drug company, received a Food and Drug Administration warning letter in December 2009 that detailed "significant" manufacturing violations, and fixing the problems took longer than the company initially expected.

The...